A Phase 3 interventional study of Durvalumab (MEDI4736) and Paclitaxel + carboplatin in Non Small Cell Lung Carcinoma NSCLC, sponsored by AstraZeneca. Active, not recruiting at 92 sites in 12 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.
Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by enrollment, is one of 10 that started in 2017, is one of 17 in phase 3, reaches primary completion later than 4 of the 36 other live ones, and was the 22nd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
AstraZeneca · Sites in Australia, Georgia, Poland and 2 more countries
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
ETOP IBCSG Partners Foundation · Sites in Australia, Austria, Belgium and 7 more countries
Ages 18+
Idris Bahce · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, durvalumab is the treatment under test here. Read study by study →
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 62 · Phase 3 17 · Phase 4 2
First in 2013; this study’s year is marked. 10 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 669 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 74 across the 94 interventional studies. Of the 47 that completed or were terminated, 27 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 94 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca: 25 open now, 78 under way, 28 of them phase 3. Of 123 finished, 45 (37%) have results posted.
Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 23rd largest by enrollment of the 137 interventional ones that give a count, is one of 8 that started in 2017, is one of 44 in phase 3, reaches primary completion later than 8 of the 77 other live ones, and was the 88th registered.
AstraZeneca’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
8 of the studies testing durvalumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04465968Phase 3National Cancer Center Hospital EastEfficacy and Safety of CRT, Durvalumab and Surgery for SST | 2027-08-31 |
| NCT03965468ETOP IBCSG Partners FoundationImmunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC | 2026-12 |
| NCT04245514Swiss Cancer InstituteMultimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) | 2026-12-07 |
| NCT06908070Idris BahceChemoradiotherapy With Surgery Followed by Consolidation Durvalumab | 2026-12-17 |
| NCT05206812Yonsei UniversityWindow of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE) | 2027-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among AstraZeneca’s 209 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type and with PD-L1 high expression (PEARL)
Patients with stage IV NSCLC will be randomized in a 1:1 ratio to 2 treatment arms (durvalumab or SOC therapy). The dual primary objectives of this study are to assess the efficacy of durvalumab versus SoC in terms of OS (Overall Survival) in all randomized patients and in patients who are at low risk of EM (early mortality)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-PD-L1 monoclonal Antibody monotherapy
Drug: Durvalumab (MEDI4736)
Standard of Care Platinum-Based chemotherapy
Drug: Paclitaxel + carboplatin · Drug: Gemcitabine + cisplatin · Drug: Gemcitabine + carboplatin · Drug: Pemetrexed + cisplatin · Drug: Pemetrexed + carboplatin
Anti-PD-L1 monoclonal Antibody monotherapy
Drug pages: Paclitaxel · Carboplatin
Chemotherapy Agents
Also known as: Platinum based Standard of Care Chemotherapy
Drug pages: Gemcitabine · Cisplatin
Chemotherapy Agents
Also known as: Platinum based Standard of Care Chemotherapy
Drug pages: Gemcitabine · Carboplatin
Chemotherapy Agents
Also known as: Platinum based Standard of Care Chemotherapy
Drug pages: Pemetrexed · Cisplatin
Chemotherapy Agent
Also known as: Platinum based Standard of Care Chemotherapy
Drug pages: Pemetrexed · Carboplatin
Chemotherapy Agent
Also known as: Platinum based Standard of Care Chemotherapy
Overall Survival (OS)
OS is defined as the time from the date of randomization until death due to any cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.
Time frame: From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months [data cut-off (DCO) 27 October 2022]
OS in Participants With LREM
OS is defined as the time from the date of randomization until death due to any cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.
Time frame: From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months (DCO 27 October 2022)
OS in PD-L1 TC >= 50% Analysis Set
OS is defined as the time from the date of randomization until death due to any cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.
Time frame: From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months (DCO 27 October 2022)
OS in PD-L1 TC >= 50% LREM Analysis Set
OS is defined as the time from the date of randomization until death due to ay cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.
Time frame: From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months (DCO 27 October 2022)
Progression Free Survival (PFS) Based on Investigator Assessment According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
The PFS (per RECIST 1.1) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1). Progression of disease per RECIST 1.1, when either 1 of the criteria met: Target lesion (TL): at least a 20% increase in the sum of diameters of TLs, for reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Non-target lesion (NTL): Unequivocal progression of existing NTLs. It may be due to an important progression in 1 lesion only or in several lesions. In all cases the progression must be clinically significant for the physician to consider changing (or stopping) therapy. New lesions: the presence of 1 or more new lesions was assessed as progression.
Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months DCO 27 October 2022)
PFS Based on Investigator Assessment According to RECIST 1.1 in LREM Analysis Set
The PFS (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1).
Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% Analysis Set
The PFS (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1).
Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% LREM Analysis Set
The PFS (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1).
Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
Objective Response Rate (ORR) as Per RECIST 1.1 Using Investigator Assessment
ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with an unconfirmed response of complete response (CR) or partial response (PR). CR was defined as disappearance of all target lesions (TLs). Any pathological lymph nodes selected as TLs had a reduction in short axis to \< 10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.
Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 25% LREM Analysis Set
ORR (per RECIST 1.1 using Investigator assessments)was defined as the percentage of participants with an unconfirmed response of CR or PR. CR was defined as disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.
Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% Analysis Set
ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with an unconfirmed response of CR or PR. CR was defined as disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.
Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% LREM Analysis Set
ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with an unconfirmed response of CR or PR. CR was defined as disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.
Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
Duration of Response (DoR) as Per RECIST 1.1 Using Investigator Assessment
DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.
Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=25% LREM Analysis Set
DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.
Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% Analysis Set
DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.
Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% LREM Analysis Set
DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.
Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
Alive and Progression-Free at 12 Months (APF12)
The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.
Time frame: From date of randomization until 12 months
APF12 in PD-L1 TC >= 25% LREM Analysis Set
The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.
Time frame: From date of randomization until 12 months
APF12 in PD-L1 TC >= 50% Analysis Set
The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.
Time frame: From date of randomization until 12 months
APF12 in PD-L1 TC >= 50% LREM Analysis Set
The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.
Time frame: From date of randomization until 12 months
Time From Randomization to Second Progression (PFS2)
PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.
Time frame: Tumor assessments (per RECIST 1.1) until confirmed objective disease progression. Disease then assessed as per local practice until 2nd progression or death (up to a maximum of approximately 69 months)
PFS2 in PD-L1 TC >= 25% LREM Analysis Set
PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.
Time frame: Tumor assessments (per RECIST 1.1) until confirmed objective disease progression. Disease then assessed as per local practice until 2nd progression or death (up to a maximum of approximately 69 months)
PFS2 in PD-L1 TC >= 50% Analysis Set
PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.
Time frame: Tumor assessments (per RECIST 1.1) until confirmed objective disease progression. Disease then assessed as per local practice until 2nd progression or death (up to a maximum of approximately 69 months)
PFS2 in PD-L1 TC >= 50% LREM Analysis Set
PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.
Time frame: Tumor assessments (per RECIST 1.1) until confirmed objective disease progression. Disease then assessed as per local practice until 2nd progression or death (up to a maximum of approximately 69 months)
OS at 18 Months
OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.
Time frame: From date of randomization till 18 months.
OS at 18 Months in PD-L1 TC > = 25% LREM Analysis Set
OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.
Time frame: From date of randomization till 18 months
OS at 18 Months in PD-L1 TC >= 50% Analysis Set
OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.
Time frame: From date of randomization till 18 months
OS at 18 Months in PD-L1 TC >= 50% LREM Analysis Set
OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.
Time frame: From date of randomization till 18 months
OS at 24 Months
OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.
Time frame: From date of randomization till 24 months
OS at 24 Months in PD-L1 TC > = 25% LREM Analysis Set
OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.
Time frame: From date of randomization till 24 months
OS at 24 Months in PD-L1 TC >= 50% Analysis Set
OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.
Time frame: From date of randomization till 24 months
OS at 24 Months in PD-L1 TC >= 50% LREM Analysis Set
OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.
Time frame: From date of randomization till 24 months
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) 30-Item Core Quality of Life Questionnaire Version 3 (QLQ-C30)
The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual. An outcome variable consisted of a score from 0 to 100. Higher scores on the global health status and functioning scales indicate better health status/function, but higher scores on symptom scales/items represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The mixed model repeated measures (MMRM) analysis of EORTC QLQ-C30 considered all data from baseline to PD or 12 months.
Time frame: Baseline and 12 months
Change From Baseline in EORTC QLQ-C30 in PD-L1 TC >= 25% LREM Analysis Set
The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual. An outcome variable consisted of a score from 0 to 100. Higher scores on the global health status and functioning scales indicate better health status/function, but higher scores on symptom scales/items represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The MMRM analysis of EORTC QLQ-C30 considered all data from baseline to PD or 12 months.
Time frame: Baseline and 12 months
Time to Deterioration of EORTC QLQ-C30
Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful deterioration (a decrease in the function scales or the global health status/ health-related quality of life \[HRQoL\] from baseline of ≥10) that was confirmed at a subsequent visit or death in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual.
Time frame: From randomization until date of first symptom deterioration that is confirmed, assessed up to a maximum of approximately 69 months (DCO 27 October 2022)
Time to Deterioration of EORTC QLQ-C30 in PD-L1 TC >= 25% LREM Analysis Set
Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful deterioration a decrease in the function scales or the global health status/ HRQoL from baseline of ≥10) that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual.
Time frame: From randomization until date of first symptom deterioration that is confirmed, assessed up to a maximum of approximately 69 months (DCO 27 October 2022)
Change From Baseline in EORTC 13-Item Lung Cancer Quality of Life Questionnaire (QLQ-LC13)
The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication. An outcome variable consisted of a score from 0 to 100. Higher scores on symptom scales represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The MMRM analysis of EORTC QLQ-LC13 considered all data from baseline to PD or 12 months.
Time frame: Baseline and 12 months
Change From Baseline in EORTC QLQ-LC13 in PD-L1 TC >= 25% LREM Analysis Set
The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication. An outcome variable consisted of a score from 0 to 100. Higher scores on symptom scales represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The MMRM analysis of EORTC QLQ-LC13 considered all data from baseline to PD or 12 months.
Time frame: Baseline and 12 months
Time to Deterioration of EORTC QLQ-LC13
Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful symptom deterioration a decrease in the function scales or the global health status/ HRQoL from baseline of ≥10) that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication.
Time frame: From randomization until date of first symptom deterioration that is confirmed, assessed up to maximum of approximately 69 months (DCO 27 October 2022)
Time to Deterioration of EORTC QLQ-LC13 in PD-L1 TC >= 25% LREM Analysis Set
Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful symptom deterioration a decrease in the function scales or the global health status/ HRQoL from baseline of ≥10) that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication.
Time frame: From randomization until date of first symptom deterioration that is confirmed, assessed up to maximum of approximately 69 months (DCO 27 October 2022)
Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status
ECOG performance status was assessed at the times specified based on the following and scored as 0: fully active: able to carry out all usual activities without restrictions. 1: Restricted in strenuous activity, but ambulatory and able to carry out any work activities; up and about more than 50% of waking hours. 3: Capable of only limited self-care; confined to bed or chair more than 50% of waking hours. 4: Completely disabled; unable to carry out any self-care and totally confined to bed or chair and 5: death. Data for only participants with restricted activity has been reported.
Time frame: From Baseline and until follow-up period of 57 months
Number of Participants With ECOG Performance Status in PD-L1 TC >=25% LREM Analysis Set
ECOG performance status was assessed at the times specified based on the following and scored as 0: fully active: able to carry out all usual activities without restrictions. 1: Restricted in strenuous activity, but ambulatory and able to carry out any work activities; up and about more than 50% of waking hours. 3: Capable of only limited self-care; confined to bed or chair more than 50% of waking hours. 4: Completely disabled; unable to carry out any self-care and totally confined to bed or chair and 5: death. Data for only participants with restricted activity has been reported.
Time frame: From Baseline and until follow-up period of 57 months
Percentage of Participants With Antidrug Antibody (ADA) Response to Durvalumab
Treatment-emergent ADA positive was defined as either treatment-induced or treatment-boosted ADA. Treatment-boosted ADA was defined as a baseline positive ADA titer that was boosted to a 4-fold or higher-level following study drug administration. Persistently positive was defined as positive at least 2 post-baseline assessments with at least 16 weeks between the first and last positive assessment or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.
Time frame: Up to 24 weeks
Percentage of Participants With ADA Response to Durvalumab in LREM Analysis Set
Treatment-emergent ADA positive was defined as either treatment-induced or treatment-boosted ADA. Treatment-boosted ADA was defined as a baseline positive ADA titer that was boosted to a 4-fold or higher-level following study drug administration. Persistently positive was defined as positive at least 2 post-baseline assessments with at least 16 weeks between the first and last positive assessment or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.
Time frame: Up to 24 weeks
This Phase III, open-label, multi-center study was conducted in participants with programmed cell death ligand 1 (PD-L1)- tumor cell (TC) \>= 25% advanced non small-cell lung cancer (NSCLC) at 85 centers in 10 countries (China, Russia, Hungary, Poland, South Korea, Vietnam, Turkey, Australia, Taiwan, and Thailand). First participant was enrolled on 02 January 2017 and last participant was enrolled on 25 January 2019.
| Milestone | Durvalumab | Platinum-based SoC |
|---|---|---|
| Started | 335 | 334 |
| Pd l1 tc ≥ 25% lrem analysis set | 278 | 271 |
| Pd l1 tc ≥ 50% analysis set | 247 | 246 |
| Pd l1 tc ≥ 50% lrem analysis set | 207 | 199 |
| Completed | 1 | 0 |
| Not completed | 334 | 334 |
| Withdrew: Withdrawal by subject | 5 | 17 |
| Withdrew: Death | 274 | 277 |
| Withdrew: Participants ongoing at dco | 55 | 40 |
OS is defined as the time from the date of randomization until death due to any cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.
| months | Durvalumab | Platinum-based SoC |
|---|---|---|
| Overall Survival (OS) | 14.6 (12.2 to 16.9) | 12.8 (10.1 to 14.7) |
OS is defined as the time from the date of randomization until death due to any cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.
| months | Durvalumab | Platinum-based SoC |
|---|---|---|
| OS in Participants With LREM | 14.6 (12.6 to 17.2) | 15.0 (13.1 to 16.8) |
OS is defined as the time from the date of randomization until death due to any cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.
| months | Durvalumab | Platinum-based SoC |
|---|---|---|
| OS in PD-L1 TC >= 50% Analysis Set | 14.6 (12.0 to 17.7) | 11.8 (9.8 to 14.7) |
OS is defined as the time from the date of randomization until death due to ay cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.
| months | Durvalumab | Platinum-based SoC |
|---|---|---|
| OS in PD-L1 TC >= 50% LREM Analysis Set | 14.9 (12.6 to 19.0) | 14.9 (11.8 to 17.7) |
The PFS (per RECIST 1.1) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1). Progression of disease per RECIST 1.1, when either 1 of the criteria met: Target lesion (TL): at least a 20% increase in the sum of diameters of TLs, for reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Non-target lesion (NTL): Unequivocal progression of existing NTLs. It may be due to an important progression in 1 lesion only or in several lesions. In all cases the progression must be clinically significant for the physician to consider changing (or stopping) therapy. New lesions: the presence of 1 or more new lesions was assessed as progression.
| months | Durvalumab | Platinum-based SoC |
|---|---|---|
| Progression Free Survival (PFS) Based on Investigator Assessment According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | 5.4 (4.2 to 5.7) | 4.8 (4.3 to 5.6) |
The PFS (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1).
| months | Durvalumab | Platinum-based SoC |
|---|---|---|
| PFS Based on Investigator Assessment According to RECIST 1.1 in LREM Analysis Set | 5.5 (4.4 to 6.4) | 5.6 (4.8 to 5.9) |
The PFS (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1).
| months | Durvalumab | Platinum-based SoC |
|---|---|---|
| PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% Analysis Set | 5.6 (4.7 to 6.5) | 4.5 (4.2 to 5.6) |
The PFS (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1).
| months | Durvalumab | Platinum-based SoC |
|---|---|---|
| PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% LREM Analysis Set | 5.7 (5.3 to 7.0) | 5.5 (4.2 to 5.7) |
ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with an unconfirmed response of complete response (CR) or partial response (PR). CR was defined as disappearance of all target lesions (TLs). Any pathological lymph nodes selected as TLs had a reduction in short axis to \< 10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.
| percentage of participants | Durvalumab | Platinum-based SoC |
|---|---|---|
| Objective Response Rate (ORR) as Per RECIST 1.1 Using Investigator Assessment | 37.6 (0.324 to 0.430) | 37.4 (0.322 to 0.429) |
ORR (per RECIST 1.1 using Investigator assessments)was defined as the percentage of participants with an unconfirmed response of CR or PR. CR was defined as disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.
| percentage of participants | Durvalumab | Platinum-based SoC |
|---|---|---|
| ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 25% LREM Analysis Set | 38.5 (0.327 to 0.445) | 40.2 (0.343 to 0.463) |
ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with an unconfirmed response of CR or PR. CR was defined as disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.
| percentage of participants | Durvalumab | Platinum-based SoC |
|---|---|---|
| ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% Analysis Set | 42.1 (0.359 to 0.485) | 40.7 (0.345 to 0.471) |
ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with an unconfirmed response of CR or PR. CR was defined as disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.
| percentage of participants | Durvalumab | Platinum-based SoC |
|---|---|---|
| ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% LREM Analysis Set | 44.0 (0.371 to 0.510) | 43.7 (0.367 to 0.509) |
DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.
| months | Durvalumab | Platinum-based SoC |
|---|---|---|
| Duration of Response (DoR) as Per RECIST 1.1 Using Investigator Assessment | 11.9 (9.7 to 18.7) | 4.2 (3.3 to 4.6) |
DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.
| months | Durvalumab | Platinum-based SoC |
|---|---|---|
| DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=25% LREM Analysis Set | 11.6 (8.2 to 15.7) | 4.2 (4.0 to 5.4) |
DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.
| months | Durvalumab | Platinum-based SoC |
|---|---|---|
| DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% Analysis Set | 12.2 (8.3 to 21.2) | 4.2 (3.0 to 4.6) |
DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.
| months | Durvalumab | Platinum-based SoC |
|---|---|---|
| DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% LREM Analysis Set | 12.2 (8.2 to 19.7) | 4.2 (3.9 to 5.4) |
The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.
| percentage of participants | Durvalumab | Platinum-based SoC |
|---|---|---|
| Alive and Progression-Free at 12 Months (APF12) | 25.5 (20.8 to 30.4) | 13.3 (9.6 to 17.5) |
The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.
| percentage of participants | Durvalumab | Platinum-based SoC |
|---|---|---|
| APF12 in PD-L1 TC >= 25% LREM Analysis Set | 24.1 (19.1 to 29.5) | 16.4 (11.9 to 21.5) |
The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.
| percentage of participants | Durvalumab | Platinum-based SoC |
|---|---|---|
| APF12 in PD-L1 TC >= 50% Analysis Set | 26.1 (20.7 to 31.9) | 11.7 (7.7 to 16.5) |
The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.
| percentage of participants | Durvalumab | Platinum-based SoC |
|---|---|---|
| APF12 in PD-L1 TC >= 50% LREM Analysis Set | 26.5 (20.5 to 32.8) | 14.5 (9.6 to 20.4) |
PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.
| months | Durvalumab | Platinum-based SoC |
|---|---|---|
| Time From Randomization to Second Progression (PFS2) | 11.3 (9.8 to 12.7) | 9.3 (8.1 to 10.7) |
PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.
| months | Durvalumab | Platinum-based SoC |
|---|---|---|
| PFS2 in PD-L1 TC >= 25% LREM Analysis Set | 11.8 (10.1 to 12.9) | 10.9 (9.3 to 13.1) |
PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.
| months | Durvalumab | Platinum-based SoC |
|---|---|---|
| PFS2 in PD-L1 TC >= 50% Analysis Set | 11.3 (9.7 to 12.9) | 8.8 (8.0 to 10.9) |
PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.
| months | Durvalumab | Platinum-based SoC |
|---|---|---|
| PFS2 in PD-L1 TC >= 50% LREM Analysis Set | 12.0 (10.1 to 13.8) | 10.9 (8.8 to 13.1) |
OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.
| percentage of participants | Durvalumab | Platinum-based SoC |
|---|---|---|
| OS at 18 Months | 42.5 (37.1 to 47.7) | 34.2 (29.0 to 39.4) |
OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.
| percentage of participants | Durvalumab | Platinum-based SoC |
|---|---|---|
| OS at 18 Months in PD-L1 TC > = 25% LREM Analysis Set | 43.0 (37.1 to 48.8) | 41.4 (35.4 to 47.4) |
OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.
| percentage of participants | Durvalumab | Platinum-based SoC |
|---|---|---|
| OS at 18 Months in PD-L1 TC >= 50% Analysis Set | 43.2 (36.9 to 49.3) | 34.9 (28.8 to 41.0) |
OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.
| percentage of participants | Durvalumab | Platinum-based SoC |
|---|---|---|
| OS at 18 Months in PD-L1 TC >= 50% LREM Analysis Set | 44.3 (37.4 to 51.0) | 42.2 (35.2 to 49.1) |
OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.
| percentage of participants | Durvalumab | Platinum-based SoC |
|---|---|---|
| OS at 24 Months | 34.6 (29.5 to 39.7) | 27.2 (22.4 to 32.1) |
OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.
| percentage of participants | Durvalumab | Platinum-based SoC |
|---|---|---|
| OS at 24 Months in PD-L1 TC > = 25% LREM Analysis Set | 34.7 (29.1 to 40.3) | 32.8 (27.2 to 38.6) |
OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.
| percentage of participants | Durvalumab | Platinum-based SoC |
|---|---|---|
| OS at 24 Months in PD-L1 TC >= 50% Analysis Set | 37.0 (31.0 to 43.1) | 27.0 (21.5 to 32.8) |
OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.
| percentage of participants | Durvalumab | Platinum-based SoC |
|---|---|---|
| OS at 24 Months in PD-L1 TC >= 50% LREM Analysis Set | 36.9 (30.3 to 43.5) | 32.6 (26.1 to 39.3) |
The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual. An outcome variable consisted of a score from 0 to 100. Higher scores on the global health status and functioning scales indicate better health status/function, but higher scores on symptom scales/items represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The mixed model repeated measures (MMRM) analysis of EORTC QLQ-C30 considered all data from baseline to PD or 12 months.
| scores on a scale | Durvalumab | Platinum-based SoC |
|---|---|---|
| Global health status | -0.7 ± 1.19 | -7.4 ± 1.27 |
| Physical functioning | -3.3 ± 1.23 | -6.1 ± 1.30 |
| Fatigue | 1.4 ± 1.33 | 7.2 ± 1.43 |
| Appetite loss | -1.1 ± 1.39 | 9.1 ± 1.50 |
The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual. An outcome variable consisted of a score from 0 to 100. Higher scores on the global health status and functioning scales indicate better health status/function, but higher scores on symptom scales/items represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The MMRM analysis of EORTC QLQ-C30 considered all data from baseline to PD or 12 months.
| scores on a scale | Durvalumab | Platinum-based SoC |
|---|---|---|
| Global health status | -1.4 ± 1.23 | -7.3 ± 1.31 |
| Physical functioning | -3.9 ± 1.22 | -6.0 ± 1.29 |
| Fatigue | 2.2 ± 1.33 | 7.7 ± 1.42 |
| Appetite loss | -0.2 ± 1.43 | 9.8 ± 1.52 |
Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful deterioration (a decrease in the function scales or the global health status/ health-related quality of life \[HRQoL\] from baseline of ≥10) that was confirmed at a subsequent visit or death in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual.
| months | Durvalumab | Platinum-based SoC |
|---|---|---|
| Global health status | 7.3 (5.5 to 9.1) | 3.8 (3.6 to 5.5) |
| Physical functioning | 7.4 (5.6 to 9.8) | 3.8 (3.6 to 5.2) |
| Appetite loss | 9.2 (7.3 to 11.4) | 3.6 (2.3 to 3.8) |
| Fatigue | 4.9 (3.7 to 7.0) | 1.8 (1.6 to 2.6) |
Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful deterioration a decrease in the function scales or the global health status/ HRQoL from baseline of ≥10) that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual.
| months | Durvalumab | Platinum-based SoC |
|---|---|---|
| Global health status | 7.4 (5.6 to 9.2) | 5.5 (3.7 to 6.5) |
| Physical functioning | 7.4 (5.6 to 10.1) | 4.7 (3.7 to 5.8) |
| Appetite loss | 9.3 (7.3 to 11.6) | 3.7 (2.6 to 5.0) |
| Fatigue | 5.5 (3.8 to 7.4) | 1.8 (1.6 to 3.3) |
The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication. An outcome variable consisted of a score from 0 to 100. Higher scores on symptom scales represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The MMRM analysis of EORTC QLQ-LC13 considered all data from baseline to PD or 12 months.
| scores on a scale | Durvalumab | Platinum-based SoC |
|---|---|---|
| Cough | -6.4 ± 1.30 | -7.9 ± 1.41 |
| Dyspnea | 2.4 ± 1.24 | 4.1 ± 1.32 |
| Chest pain | -1.0 ± 1.26 | -0.2 ± 1.37 |
The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication. An outcome variable consisted of a score from 0 to 100. Higher scores on symptom scales represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The MMRM analysis of EORTC QLQ-LC13 considered all data from baseline to PD or 12 months.
| scores on a scale | Durvalumab | Platinum-based SoC |
|---|---|---|
| Cough | -6.6 ± 1.38 | -8.6 ± 1.48 |
| Dyspnea | 2.9 ± 1.28 | 3.9 ± 1.35 |
| Chest pain | -0.7 ± 1.30 | -1.0 ± 1.40 |
Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful symptom deterioration a decrease in the function scales or the global health status/ HRQoL from baseline of ≥10) that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication.
| months | Durvalumab | Platinum-based SoC |
|---|---|---|
| Cough | 7.5 (6.4 to 10.1) | 6.6 (5.6 to 8.2) |
| Dyspnea | 2.8 (1.9 to 4.6) | 3.6 (2.4 to 3.8) |
| Chest pain | 9.0 (6.3 to 11.9) | 6.4 (4.6 to 7.2) |
Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful symptom deterioration a decrease in the function scales or the global health status/ HRQoL from baseline of ≥10) that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication.
| months | Durvalumab | Platinum-based SoC |
|---|---|---|
| Cough | 9.2 (6.4 to 12.3) | 8.2 (6.4 to 11.1) |
| Dyspnea | 3.6 (2.0 to 4.7) | 3.6 (2.4 to 3.8) |
| Chest pain | 9.8 (6.4 to 12.6) | 6.6 (5.8 to 9.2) |
ECOG performance status was assessed at the times specified based on the following and scored as 0: fully active: able to carry out all usual activities without restrictions. 1: Restricted in strenuous activity, but ambulatory and able to carry out any work activities; up and about more than 50% of waking hours. 3: Capable of only limited self-care; confined to bed or chair more than 50% of waking hours. 4: Completely disabled; unable to carry out any self-care and totally confined to bed or chair and 5: death. Data for only participants with restricted activity has been reported.
| number of participants | Durvalumab | Platinum-based SoC |
|---|---|---|
| Restricted activity, Baseline | 267 | 255 |
| Restricted activity, Follow-up Month 57 | 0 | 2 |
ECOG performance status was assessed at the times specified based on the following and scored as 0: fully active: able to carry out all usual activities without restrictions. 1: Restricted in strenuous activity, but ambulatory and able to carry out any work activities; up and about more than 50% of waking hours. 3: Capable of only limited self-care; confined to bed or chair more than 50% of waking hours. 4: Completely disabled; unable to carry out any self-care and totally confined to bed or chair and 5: death. Data for only participants with restricted activity has been reported.
| number of participants | Durvalumab | Platinum-based SoC |
|---|---|---|
| Restricted activity, Baseline | 221 | 203 |
| Restricted activity, Follow-up Month 57 | 0 | 2 |
Treatment-emergent ADA positive was defined as either treatment-induced or treatment-boosted ADA. Treatment-boosted ADA was defined as a baseline positive ADA titer that was boosted to a 4-fold or higher-level following study drug administration. Persistently positive was defined as positive at least 2 post-baseline assessments with at least 16 weeks between the first and last positive assessment or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.
| percentage of participants | Durvalumab |
|---|---|
| Treatment-emergent ADA positive | 0.8 |
| Treatment-boosted ADA | 0.4 |
| Persistently positive | 0 |
| Transiently positive | 0.8 |
Treatment-emergent ADA positive was defined as either treatment-induced or treatment-boosted ADA. Treatment-boosted ADA was defined as a baseline positive ADA titer that was boosted to a 4-fold or higher-level following study drug administration. Persistently positive was defined as positive at least 2 post-baseline assessments with at least 16 weeks between the first and last positive assessment or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.
| percentage of participants | Durvalumab |
|---|---|
| Treatment-emergent ADA positive | 1.0 |
| Treatment-boosted ADA | 0.5 |
| Persistently positive | 0 |
| Transiently positive | 1.0 |
Collected over From first administration of study treatment up to 90 days after the last dose of durvalumab or 30 days after last dose of platinum based SoC or date of initiation of the first subsequent therapy, whichever occurs first, for approximately 69 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Durvalumab | 274/335 (81.8%) | 132/335 (39.4%) | 271/335 (80.9%) |
| Platinum-based SoC | 277/334 (82.9%) | 104/327 (31.8%) | 294/327 (89.9%) |
| Event | Durvalumab | Platinum-based SoC |
|---|---|---|
| PneumoniaInfections and infestations | 26/335 | 17/327 |
| AnaemiaBlood and lymphatic system disorders | 5/335 | 19/327 |
| MyelosuppressionBlood and lymphatic system disorders | 1/335 | 14/327 |
| Platelet count decreasedInvestigations | 0/335 | 8/327 |
| DeathGeneral disorders | 7/335 | 1/327 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 6/335 | 1/327 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/335 | 4/327 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 5/335 | 4/327 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 5/335 | 0/327 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 5/335 | 1/327 |
| Event | Durvalumab | Platinum-based SoC |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 81/335 | 168/327 |
| NauseaGastrointestinal disorders | 28/335 | 107/327 |
| Decreased appetiteMetabolism and nutrition disorders | 66/335 | 94/327 |
| Neutrophil count decreasedInvestigations | 9/335 | 85/327 |
| White blood cell count decreasedInvestigations | 13/335 | 84/327 |
| VomitingGastrointestinal disorders | 17/335 | 59/327 |
| ConstipationGastrointestinal disorders | 32/335 | 57/327 |
| Platelet count decreasedInvestigations | 15/335 | 56/327 |
| NeutropeniaBlood and lymphatic system disorders | 4/335 | 54/327 |
| LeukopeniaBlood and lymphatic system disorders | 1/335 | 51/327 |
The Full analysis set (FAS) included all randomized participants.
| Age, Continuous(years) | Durvalumab | Platinum-based SoC | Total |
|---|---|---|---|
| Mean | 60.7 ± 9.73 | 61.9 ± 8.71 | 61.3 ± 9.25 |
| Sex: Female, Male(Participants) | Durvalumab | Platinum-based SoC | Total |
|---|---|---|---|
| Female | 67 | 65 | 132 |
| Male | 268 | 269 | 537 |
| Race/Ethnicity, Customized(Participants) | Durvalumab | Platinum-based SoC | Total |
|---|---|---|---|
| White | 73 | 61 | 134 |
| Asian | 262 | 273 | 535 |
| Race/Ethnicity, Customized(Participants) | Durvalumab | Platinum-based SoC | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 6 | 8 |
| Not Hispanic or Latino | 333 | 328 | 661 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jan 2017 to primary completion in Oct 2022, 69 months.
Results were first posted in Dec 2023, 1 year 1 month after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 69 months is above that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Durvalumab
Carcinoma, Non-Small-Cell Lung →